-
Jan 24, 2022
ADOPTION OF THE 2022 RESTRICTED SHARE UNIT SCHEME
-
Jan 10, 2022
40th Annual J.P. Morgan Healthcare Conference Presentation
-
Nov 18, 2021
R&D Day Mandarin Session2 – Live Webcast
-
Dec 30, 2021
Antengene Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors
-
Dec 29, 2021
XPOVIO®
-
Dec 20, 2021
Business Update Call on NMPA Granted Marketing Approval for XPOVIO (ATG-010/selinexor) in China
